Clinical Trials Browser

Phase 2 × Neoplasm, Residual × Immunotherapy × Clear all

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual